Emory Gynecologist Says Vaccine Will Help Protect Women Against Cervical Cancer

In a seperate reports from Emory University and The University of Queensland "The results of a major clinical trial involving 12,167 women shows Gardasil, a genetically-engineered vaccine by Merck & Co., was 100 percent effective in preventing persistent infection with the two major strains of the human papillomavirus (HPV) that account for 70 percent of cervical cancer cases. As far as a cancer vaccine goes, this is the best we have," says Dr. Ault, of Emory, who has spent much of his career researching the HPV vaccine. "In four or five generations we've gone from cervical cancer being the most common cause of cancer death in the United States for women to being a vaccine-preventable disease. That's a really remarkable story if you trace this research over the last 50 to 60 years."
Dr Ian Frazer of UQ's Centre for Immunology and Cancer Research said "It is very rare, almost unheard of, to achieve a 100% efficacy rate in any treatment, so these results are truly wonderful”